LoadingLoadingLoadingThe quick read
Latest quote·Oct 16
Net selling: insiders sold $61.6M and bought $0 on the open market in 90 days (SEC Form 4). Congress: net selling of $1K to $15K in 180 days.
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsNet selling: insiders sold $61.6M and bought $0 of TMO stock on the open market in the 90 days to Oct 18, 2026, according to SEC Form 4 filings. $50.9M of the sales were made under pre-set Rule 10b5-1 trading plans. The largest was Casper, Marc N (Chairman & CEO), who sold $32.8M. The latest filing was on Sep 1, 2026.
Rep. Dwight Evans (D) sold $1K to $15K on May 7, 2026, disclosed 8 days later. In total, 1 member disclosed 1 TMO trade with trade dates in the last 180 days, filed a median 8 days after trading.
This summary uses filings available on Oct 18, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
8 funds hold a position and insiders have been net selling.
Buys/Adds (3)
Viking Global
$511.7M
added
Glenview Capital
$191.3M
added
D.E. Shaw
$172.8M
added
Sells (2)
No tracked top-trader positions in TMO right now.
Live Hyperliquid positioning - not every stock is covered
Last report
Jul 23, 2026
Financial period
Q2 2026
Adjusted EPS
$5.71 expected
Revenue
No comparable estimate
| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / estimate | Rev. surprise |
|---|---|---|---|---|---|
| Jun 30, 2026 | Jul 23, 2026 | $6.03 / $5.71Yahoo Finance | +5.58% beat | $11.99B / Unavailable | Unavailable |
| Mar 31, 2026 | Apr 23, 2026 | $5.44 / $5.24Yahoo Finance | +3.79% beat | Unavailable | Unavailable |
| Dec 31, 2025 | Jan 29, 2026 | $6.57 / $6.45Yahoo Finance | +1.87% beat | Unavailable | Unavailable |
| Sep 30, 2025 | Oct 22, 2025 | $5.79 / $5.50Yahoo Finance | +5.32% beat | Unavailable | Unavailable |
| Jun 30, 2025 | Jul 23, 2025 | $5.36 / $5.23Alpha Vantage | +2.49% beat | Unavailable | Unavailable |
| Mar 31, 2025 | Apr 23, 2025 | $5.15 / $5.10Alpha Vantage | +0.98% in line | Unavailable | Unavailable |
| Dec 31, 2024 | Jan 30, 2025 | $6.10 / $5.94Alpha Vantage | +2.69% beat | Unavailable | Unavailable |
| Sep 30, 2024 | Oct 23, 2024 | $5.28 / $5.25Alpha Vantage | +0.57% in line | Unavailable | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue uses company releases and saved estimates.
Estimates as of Oct 18, 2026
EPS expected
$6.33 to $6.47
Revenue expected
19 analysts
Last 30 days
Analysts cutting estimates
Estimate drift
Change in 30 days
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $11.12B | $12.21B | $11.01B | $11.99B |
| Cost of what it sold | $6.54B | $7.20B | $6.53B | $7.05B |
| Gross profit | $4.58B | $5.01B | $4.48B | $4.94B |
| What it spent | ||||
| Research and development | $347.0M | $357.0M | $336.0M | $364.0M |
| Sales and admin | $2.16B | $1.98B | $2.18B | $1.91B |
| Other operating costs | — | $374.0M | $96.0M | $583.0M |
| Total operating expenses | $2.51B | $2.71B | $2.61B | $2.86B |
| What was left | ||||
| Operating profit | $2.08B | $2.30B | $1.86B | $2.09B |
| Interest on debt | $347.0M | $365.0M | $354.0M | $401.0M |
| Profit before tax | $1.83B | $2.12B | $1.73B | $1.92B |
| Tax | $207.0M | $153.0M | $70.0M | $167.0M |
| Net profit | $1.62B | $1.98B | $1.65B | $1.74B |
| EBITDA | $2.83B | $3.22B | $2.62B | $2.90B |
This stock is in a strong uptrend.
Trend
Strong uptrend
100 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is bullish
Pfizer, Thermo Fisher Scientific And More: CNBC’s ‘Final Trades’
NeutralOct 15Thermo Fisher Scientific (TMO) Expands Drug Development Services, Is The Stock Fully Valued?
Leans bearishOct 15Guggenheim reiterates Thermo Fisher Scientific stock Buy rating By Investing.com
BullishOct 15Larry Robbins Opens New Position in Surgery Partners Inc (SGRY) -- Shares Look 39% Undervalued on GF Value
NeutralOct 15TD Cowen raises target for Thermo Fisher Scientific stock from USD 675 to USD 760
BullishOct 15Bruker, Sotera downgraded as J.P. Morgan reviews life sciences coverage
NeutralOct 14Thermo Fisher Scientific Inc. stock rises Wednesday, outperforms market
BullishOct 14Thermo Fisher options suggest 5.1% move on Oct. 21 earnings
NeutralOct 14